COMMUNIQUÉS West-GlobeNewswire

Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors
21/04/2026
LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, today [...]
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
21/04/2026
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator [...]
ACTG Launches Critical Study Evaluating Hormone Therapy for Women Living with HIV in the Menopause Transition
21/04/2026
CHAPEL HILL, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the HoT study (Menopausal Hormone Therapy for [...]
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21/04/2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
21/04/2026
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla [...]
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present [...]
World’s Fastest HIV Test added to the Together TakeMeHome Program for Free at Home HIV Self-Testing Across the United States
21/04/2026
bioLytical’s INSTI® HIV Self Test will support Together TakeMeHome’s national program delivering free HIV self-tests directly to individuals across the United States. Partnership Highlights bioLytical Laboratories Inc. [...]
GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews
21/04/2026
Inside the App GLP-1 Users Are Calling a Game-Changer – Reviews, Features, and What Sets It Apart NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- GLP Diet App has launched a dedicated wellness app designed to support [...]
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
21/04/2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
21/04/2026
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
21/04/2026
Formal decision expected in May 2026 ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for [...]
QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment
21/04/2026
Unaudited Q1 2026 ISP revenue of $370,000, up from $163,000 in Q1 2025, representing 127% year-over-year growth Growth supported by expanding provider adoption, the launch of the Q-Connect AOM and GLP-1 Support [...]
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
21/04/2026
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
21/04/2026
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application [...]
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
21/04/2026
Garching / Munich, April 21 , 2026 –– ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide quality of life data from its Phase 3 COMPETE trial in [...]
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
21/04/2026
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed [...]
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
21/04/2026
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing [...]
Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026
21/04/2026
Oral MYC condensate modulator drives tumor regression and stasis in preclinical models Disruption of MYC condensates enables targeted inhibition of MYC-driven gene expression Selective killing in cells with high levels [...]
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
21/04/2026
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations [...]

Pages